RadNet, Inc. Common Stock (RDNT) is a publicly traded Healthcare sector company. As of May 19, 2026, RDNT trades at $53.56 with a market cap of $4.12B and a P/E ratio of -300.31. RDNT moved -1.48% today. Year to date, RDNT is -23.65%; over the trailing twelve months it is -11.40%. Its 52-week range spans $45.00 to $93.65. Analyst consensus is strong buy with an average price target of $85.00. Rallies surfaces RDNT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Ventripoint’s VMS+ 4.0 Files for NMPA Approval, Showcases at AEPC with Multiple Partnerships: Ventripoint Diagnostics submitted its VMS+ 4.0 cardiac AI imaging system for approval via China’s NMPA green channel on April 28, targeting 330 million cardiovascular disease patients. It also exhibited at AEPC in Padua and secured U.S. and Indigenous partnerships plus an Edison Award, stacking regulatory and commercial validations.
| Metric | Value |
|---|---|
| Price | $53.56 |
| Market Cap | $4.12B |
| P/E Ratio | -300.31 |
| EPS | $-0.18 |
| Dividend Yield | 0.00% |
| 52-Week High | $93.65 |
| 52-Week Low | $45.00 |
| Volume | 133.27K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.14B |
| Net Income | $22.05M |
| Gross Margin | 0.00% |
5 analysts cover RDNT: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $85.00.